Plain-English translation of NCT06790394 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are evaluating how reliable a new imaging agent called florbetaben is for detecting amyloid protein buildup in the heart. The study involves taking the same type of scan twice to see if the results are consistent and trustworthy. This matters because doctors need reliable tests to diagnose and monitor amyloid heart disease.
Amyloid heart disease is a serious condition where abnormal proteins build up in the heart muscle, but it's often hard to diagnose. This medication is being tested to see if it can reliably highlight amyloid deposits so doctors can spot the disease earlier and track how it changes over time.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic twice—once at the start and once a few weeks later. At each visit, you would receive an injection of the imaging medication and then undergo a PET scan of your heart, which takes about an hour total. The researchers may also collect blood samples to measure how your body processes the medication. The study is designed to see if the scan results are the same both times.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United Kingdom